Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …

Immunotherapy is revolutionizing the management of multiple solid tumors, and early data
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Breast cancer has become the most commonly diagnosed cancer globally. The relapse and
metastasis of breast cancer remain a great challenge despite advances in chemotherapy …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with
potential to provide greater clinical benefit to patients with advanced-stage cancer. In …

Historically, breast cancer tumors have been considered immunologically quiescent, with
the majority of tumors demonstrating low lymphocyte infiltration, low mutational burden, and …

Canine mammary tumors (CMTs) are the most common neoplasm in intact female dogs.
Canine mammary cancer (CMC) represents 50% of CMTs, and besides surgery, which is the …

Mucins are the main structural components of mucus that create a selective protective
barrier for epithelial surface and also execute wide range of other physiological functions …

Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics
in a significant part of patients. Immunotherapeutical agents represent an emerging option …